EUVIMEDEUVIMED entdecken
Open Access

Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

J J Eertink iD, G J C Zwezerijnen iD, M W Heymans iD, S Pieplenbosch iD, S E Wiegers iD, U Dührsen iD, A Hüttmann iD, L Kurch iD, C Hanoun, P J Lugtenburg iD, S F Barrington iD, N G Mikhaeel iD und 9 weitere

Blood · 31.03.2023

DOI: 10.1182/blood.2022018558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, online erschienen am 31.03.2023. Verfasst von J J Eertink und 20 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 27-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study was to externally validate the clinicalPET model developed in the HOVON-84 trial and to compare the model performance of our clinicalPET model to the international prognostic index (IPI). In total, 1195 Diffuse large B-cell lymphoma patients were included. 887 patients from 6 studies were used as external validation datasets. Primary outcomes were 2-year progression free survival (PFS) and 2-year time to progression (TTP). Metabolic tumor volume (MTV), the maximum distance between the largest lesion and another lesion (Dmaxbulk) and the peak standardized uptake value (SUVpeak) were extracted. The predictive value of the IPI and the HOVON-84 clinicalPET model (MTV, Dmaxbulk, SUVpeak, performance status and age) were tested. Model performance was assessed using the area under the curve (AUC), and diagnostic performance with the positive predictive value (PPV). Using 2-year PFS as outcome, the IPI yielded an AUC of 0.62 (range:0.51-0.65). The clinicalPET model yielded a significantly higher AUC of 0.71 (range:0.59-0.75, p<0.001). Comparable results were found using 2-year TTP. High-risk IPI patients had a 2-year PFS of 61.4%, versus 51.9% for the high-risk clinicalPET patients, with an increase in PPV from 35.5% to 49.1%, respectively. 66.4% of high-risk IPI patients were free from progression or relapse versus 55.5% for high-risk clinicalPET patients, with an increased PPV from 33.7% to 44.6%, respectively. The clinicalPET model that was developed in the HOVON-84 dataset remained predictive of outcome in 6 independent first-line DLBCL studies, and had higher model performance than the currently used IPI in all studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalLymphoma, Large B-Cell, DiffuseHumansPrognosisRetrospective StudiesPositron-Emission TomographyRisk FactorsFluorodeoxyglucose F18

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Radiology and Nuclear Medicine, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Epidemiology and Data Science, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Methodology, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
  • Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

ORCID-Profile: J J Eertink, G J C Zwezerijnen, M W Heymans, S Pieplenbosch, S E Wiegers, U Dührsen, A Hüttmann, L Kurch, P J Lugtenburg, S F Barrington, N G Mikhaeel, L Ceriani, E Zucca, S Czibor, T Györke, M E D Chamuleau, O S Hoekstra, H C W de Vet, R Boellaard, J M Zijlstra

Förderung

  • Wellcome Trust

Zitieren

APA

Eertink, J. J., Zwezerijnen, G. J. C., Heymans, M. W., Pieplenbosch, S., Wiegers, S. E., Dührsen, U., Hüttmann, A., Kurch, L., Hanoun, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Czibor, S., Györke, T., Chamuleau, M. E. D., Hoekstra, O. S., de Vet, H. C. W., …, & Zijlstra, J. M. (2023). Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. https://doi.org/10.1182/blood.2022018558

Vancouver

Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, et al. Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023. doi:10.1182/blood.2022018558

BibTeX
@article{Eertink2023,
  author = {Eertink, J J and Zwezerijnen, G J C and Heymans, M W and Pieplenbosch, S and Wiegers, S E and Dührsen, U and Hüttmann, A and Kurch, L and Hanoun, C and Lugtenburg, P J and Barrington, S F and Mikhaeel, N G and Ceriani, L and Zucca, E and Czibor, S and Györke, T and Chamuleau, M E D and Hoekstra, O S and de Vet, H C W and Boellaard, R and Zijlstra, J M},
  title = {Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018558}
}
Kostenlos starten →